Vikram Purohit

Stock Analyst at Morgan Stanley

(1.81)
# 3,309
Out of 5,147 analysts
163
Total ratings
32.31%
Success rate
-7.58%
Average return

Stocks Rated by Vikram Purohit

COMPASS Pathways
Feb 18, 2026
Maintains: Overweight
Price Target: $11$18
Current: $6.90
Upside: +160.87%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92$94
Current: $101.27
Upside: -7.18%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31$34
Current: $26.35
Upside: +29.03%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80$79
Current: $69.53
Upside: +13.62%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4$5.89
Current: $2.74
Upside: +114.96%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.67
Upside: +36.24%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180$250
Current: $233.50
Upside: +7.07%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125$190
Current: $163.89
Upside: +15.93%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6$9
Current: $5.68
Upside: +58.45%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $29.44
Upside: +5.30%
Maintains: Equal-Weight
Price Target: $15$16
Current: $121.28
Upside: -86.81%
Maintains: Overweight
Price Target: $45$10
Current: $26.97
Upside: -62.92%
Downgrades: Equal-Weight
Price Target: $46$6
Current: $13.97
Upside: -57.05%
Maintains: Overweight
Price Target: $43$42
Current: $9.04
Upside: +364.60%
Maintains: Equal-Weight
Price Target: $38$41
Current: $91.35
Upside: -55.12%
Maintains: Equal-Weight
Price Target: $120$40
Current: $8.90
Upside: +349.44%
Initiates: Equal-Weight
Price Target: $13
Current: $2.24
Upside: +480.36%
Maintains: Equal-Weight
Price Target: $39$38
Current: $12.06
Upside: +215.09%
Maintains: Equal-Weight
Price Target: $24$20
Current: $7.08
Upside: +182.49%
Maintains: Underweight
Price Target: $11$10
Current: $18.25
Upside: -45.21%
Initiates: Overweight
Price Target: $22
Current: $1.06
Upside: +1,975.47%
Maintains: Equal-Weight
Price Target: $40$20
Current: $20.99
Upside: -4.72%